DCPrime
Leiden
About DCPrime
DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne-based vaccines share all immune-stimulatory properties with patient-derived dendritic cell-based vaccines, and have the simple logistics of off-the-shelf products. DCOne cells express a range of known tumor antigens, which are targeted in several cancer types.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $26.5M
- Last round: Series Unknown (Mar 2018)
- Website: dcprime.nl
- Phone: +31 713322627
Industries & Categories
Biotechnology, Clinical Trials, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/dcprime-104809 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.